Frontier Progress TITAN Study Japanese Subgroup Final Results Released
clinical results of oncolytic virus/PD-1 antibody combination
2022 The results of AACRCG0070 combined with pembrolizumab in the treatment of non-muscle invasive bladder cancer in stage II are encouraging
Encouraging results from 2022 AACR maveropepimut-S, intermittent low-dose cyclophosphamide combined with pembrolizumab in advanced, metastatic bladder cancer
Phase 3 clinical results of the first self-amplifying mRNA new crown vaccine were announced, with a protection rate of 55% and a severe protection rate of 95%
Blockbuster | The latest clinical research results of the innovative diabetes drug SOLIQUA™ (iGlarLixi) are released!
Courier for Hearing Loss, Positive Phase 2a Clinical Results of BDNF Therapy
Good news: ADAPT+ research results debut at AAN conference, efgartigimod is also effective and safe for long-term treatment of myasthenia gravis!
The latest clinical research results of the innovative diabetes drug iGlarLixi (basal insulin GLP-1RA compound preparation) are released!
results of broad-spectrum antibacterial drugs were positive
The "silent" virus is "activated" by the new crown, infecting 95% of adults, resulting in new crown sequelae and even terminal illness!
Master of Immunization: A Complete Summary of Academician Dong Chen's Research Results
GSK 2022Q1 results: revenue increased by 32%!
Express Oral Delivery of Biologics, Positive Phase 2 Clinical Results of Innovative Cytokine Therapy
Pancreatic cancer double immune + radiotherapy phase 2 trial achieved good results
The results of the ORIENT-15 study were released, and the immunotherapy of esophageal cancer reached a new high!
-term clinical results of Novartis CDK4/6 inhibitor are positive
Tengshengbo Pharmaceutical for the Treatment of Chronic Hepatitis B Announces the Latest Results of Phase 2 of RNAi Therapy
BeiGene to Present Clinical Results and Biomarker Data of Tislelizumab in Solid Tumors Program
Innovent Announces Preliminary Results of a Phase I Clinical Study of IBI322 (PD-L1/CD47 Bispecific